---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-197250"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T08:00:04.288548+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports new mouse-model data showing complete tumor regression and immune memory for ACR-368 and ACR-2316 combos

## Summary
- Syngeneic mouse model: sustained complete tumor regression and immune memory after multiple implant rounds over ~1 year.
- Data supports rationale for front-line combination of ACR-368 and ACR-2316 with anti-PD(L)1 agents.
- Pipeline update adds all-comer ACR-368 + ULDG ARM 3 of ongoing ACR-368-201 trial.
- AP3 platform update highlights capability to generate actionable pathway insights for novel drug design.

## SEC filing metadata
- accession: 0001193125-25-197250
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312525197250/0001193125-25-197250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312525197250/acrv-20250905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-197250
- JSON: https://secwatch.observer/filing/0001193125-25-197250.json
- Plain text: https://secwatch.observer/filing/0001193125-25-197250.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.